Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center

To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematology (Luxembourg) Jg. 29; H. 1; S. 2431958
Hauptverfasser:	Xu, Shuiqing, Chen, Wenming, Li, Yanchen
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Taylor & Francis Group 01.12.2024
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use daratumumab-based daratumumab-free Female Humans Male Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality newly-diagnosed paraskeletal plasmacytomas Plasmacytoma - diagnosis Plasmacytoma - drug therapy Plasmacytoma - mortality Retrospective Studies risk factors risk factors Multiple myeloma overall survival daratumumab-free newly-diagnosed daratumumab-based paraskeletal plasmacytomas efficacy
ISSN:	1607-8454, 1607-8454
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups. The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, = 0.002). The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
AbstractList	Objective To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).Methods The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.Results The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).Conclusions The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority. To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).OBJECTIVETo analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.METHODSThe medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).RESULTSThe results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.CONCLUSIONSThe results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority. To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups. The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, = 0.002). The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
Author	Li, Yanchen Xu, Shuiqing Chen, Wenming
Author_xml	– sequence: 1 givenname: Shuiqing surname: Xu fullname: Xu, Shuiqing organization: Beijing Chaoyang Integrative Medicine Rescue and First Aid Hospital, Beijing, People’s Republic of China – sequence: 2 givenname: Wenming surname: Chen fullname: Chen, Wenming organization: Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China – sequence: 3 givenname: Yanchen surname: Li fullname: Li, Yanchen organization: Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39589101$$D View this record in MEDLINE/PubMed
BookMark	eNpNkctu1TAQhi1URC_wCCAv2aTYsZPjsEMFSqVKbGBtTezxwcW5YDut8hi8MU7PacXGl5lP38j-z8nJOI1IyFvOLjlT7ANv2U7JRl7WrC6LFLxr1AtyttWrrXHy3_mUnKd0x1hdsx17RU5FYTvO-Bn5-xki5GVYBuirHhJaGnHvBxypmyId8SGs1HrYj9PWG5aQ_RyQDiuGaQA6Q_Y45kQffP5VbhHSbwyYIdA5QBrArLlw6SOFIs5xSjOa7O-RprzYlfqxNJIf98Vpigjja_LSQUj45rhfkJ9fv_y4-lbdfr--ufp0WxmxY7lqVCuM6XeqdbyzSjnkzDEhnGVoetv2wgk0Xe1E3THprHGNKq8HxJq12DXigtwcvHaCOz1HP0Bc9QRePxamuNcQszcBdWcdSgApLEoprQXHa8esstz24IQtrvcH1xynPwumrAefDIYAI05L0oKLWskdZ6yg747o0g9onwc_RVKA5gCY8lkpontGONNb9Poper1Fr4_Ri38i96VK
Cites_doi	10.1038/s41375-019-0660-0 10.1111/j.1600-0609.2004.00331.x 10.1007/s40262-023-01240-8 10.1111/bjh.13383 10.1038/s41375-019-0435-7 10.3324/haematol.2013.094409 10.3892/ol.2024.14381 10.1016/j.clml.2014.12.013 10.1016/j.clml.2016.08.010 10.1016/j.rcl.2015.12.008 10.1016/S1470-2045(14)70442-5 10.1007/s12253-019-00725-x 10.1016/j.clml.2022.04.014 10.1038/s41408-022-00730-5 10.1016/j.tranon.2022.101465 10.1038/leu.2011.29 10.3324/haematol.2019.219139 10.1111/bjh.13382 10.1038/sj.leu.2404284 10.1111/ejh.12377
ContentType	Journal Article
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA
DOI	10.1080/16078454.2024.2431958
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1607-8454
ExternalDocumentID	oai_doaj_org_article_9dfe4aa43de444ddaf12f0d8d1dbaf3d 39589101 10_1080_16078454_2024_2431958
Genre	Journal Article
GroupedDBID	--- 002 0YH 1~B 29I 36B 4.4 53G AAFWJ AALUX AAYXX ABDBF ACGEJ ACUHS ADCVX ADXPE AENEX AFPKN AIJEM AJWEG ALMA_UNASSIGNED_HOLDINGS AQTUD ARJSQ BLEHA BOHLJ CCCUG CITATION CS3 DU5 E01 EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P GROUPED_DOAJ H13 HCLVR HZ~ KTTOD M4Z MV1 OK1 P76 P7A P7B QZIEQ SV3 TDBHL TFL TFW TUS ~XQ 5VS ABUPF AGYJP AWYRJ CAG CGR COF CUY CVF CZDIS DRXRE ECM EIF EJD M46 NPM 7X8
ID	FETCH-LOGICAL-c370t-5863ccb786f19d88fe10f033fd0ecbd6b3f3ec92f32904fdcf58207aee206e953
IEDL.DBID	DOA
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001364306700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1607-8454
IngestDate	Fri Oct 03 12:35:36 EDT 2025 Fri Jul 11 14:48:55 EDT 2025 Mon Jul 21 06:05:12 EDT 2025 Sat Nov 29 03:45:24 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	risk factors Multiple myeloma overall survival daratumumab-free newly-diagnosed daratumumab-based paraskeletal plasmacytomas efficacy
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c370t-5863ccb786f19d88fe10f033fd0ecbd6b3f3ec92f32904fdcf58207aee206e953
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://doaj.org/article/9dfe4aa43de444ddaf12f0d8d1dbaf3d
PMID	39589101
PQID	3132847100
PQPubID	23479
ParticipantIDs	doaj_primary_oai_doaj_org_article_9dfe4aa43de444ddaf12f0d8d1dbaf3d proquest_miscellaneous_3132847100 pubmed_primary_39589101 crossref_primary_10_1080_16078454_2024_2431958
PublicationCentury	2000
PublicationDate	2024-Dec
PublicationDateYYYYMMDD	2024-12-01
PublicationDate_xml	– month: 12 year: 2024 text: 2024-Dec
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Hematology (Luxembourg)
PublicationTitleAlternate	Hematology
PublicationYear	2024
Publisher	Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis Group
References	e_1_3_2_16_1 e_1_3_2_9_1 e_1_3_2_17_1 e_1_3_2_18_1 e_1_3_2_7_1 e_1_3_2_19_1 e_1_3_2_2_1 e_1_3_2_20_1 e_1_3_2_10_1 e_1_3_2_21_1 e_1_3_2_11_1 e_1_3_2_22_1 e_1_3_2_6_1 e_1_3_2_12_1 e_1_3_2_5_1 e_1_3_2_13_1 e_1_3_2_4_1 e_1_3_2_14_1 e_1_3_2_3_1 e_1_3_2_15_1 Rosiñol L (e_1_3_2_8_1) 2012; 120
References_xml	– ident: e_1_3_2_6_1 doi: 10.1038/s41375-019-0660-0 – ident: e_1_3_2_22_1 doi: 10.1111/j.1600-0609.2004.00331.x – ident: e_1_3_2_9_1 doi: 10.1007/s40262-023-01240-8 – ident: e_1_3_2_16_1 doi: 10.1111/bjh.13383 – ident: e_1_3_2_19_1 doi: 10.1038/s41375-019-0435-7 – ident: e_1_3_2_17_1 doi: 10.3324/haematol.2013.094409 – ident: e_1_3_2_10_1 doi: 10.3892/ol.2024.14381 – ident: e_1_3_2_15_1 doi: 10.1016/j.clml.2014.12.013 – ident: e_1_3_2_5_1 doi: 10.1016/j.clml.2016.08.010 – ident: e_1_3_2_11_1 doi: 10.1016/j.rcl.2015.12.008 – ident: e_1_3_2_12_1 doi: 10.1016/S1470-2045(14)70442-5 – ident: e_1_3_2_18_1 doi: 10.1007/s12253-019-00725-x – volume: 120 start-page: 1589 issue: 8 year: 2012 ident: e_1_3_2_8_1 article-title: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. blood publication-title: The Journal of the American Society of Hematology – ident: e_1_3_2_21_1 doi: 10.1016/j.clml.2022.04.014 – ident: e_1_3_2_7_1 doi: 10.1038/s41408-022-00730-5 – ident: e_1_3_2_20_1 doi: 10.1016/j.tranon.2022.101465 – ident: e_1_3_2_2_1 doi: 10.1038/leu.2011.29 – ident: e_1_3_2_3_1 doi: 10.3324/haematol.2019.219139 – ident: e_1_3_2_14_1 doi: 10.1111/bjh.13382 – ident: e_1_3_2_13_1 doi: 10.1038/sj.leu.2404284 – ident: e_1_3_2_4_1 doi: 10.1111/ejh.12377
SSID	ssj0022070
Score	2.3515239
Snippet	To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data... To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).OBJECTIVETo... Objective To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).Methods...
SourceID	doaj proquest pubmed crossref
SourceType	Open Website Aggregation Database Index Database
StartPage	2431958
SubjectTerms	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use daratumumab-based daratumumab-free Female Humans Male Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality newly-diagnosed paraskeletal plasmacytomas Plasmacytoma - diagnosis Plasmacytoma - drug therapy Plasmacytoma - mortality Retrospective Studies risk factors
Title	Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
URI	https://www.ncbi.nlm.nih.gov/pubmed/39589101 https://www.proquest.com/docview/3132847100 https://doaj.org/article/9dfe4aa43de444ddaf12f0d8d1dbaf3d
Volume	29
WOSCitedRecordID	wos001364306700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1607-8454 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022070 issn: 1607-8454 databaseCode: DOA dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1607-8454 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022070 issn: 1607-8454 databaseCode: 0YH dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1607-8454 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022070 issn: 1607-8454 databaseCode: TFW dateStart: 19960101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogLojwXaGUkrqF-JbG5AaXqASoOgJZTZHtsqWqTrXazSPsz-o-ZyaPqBXHh4oNtOY5nkvk8Hn_D2FuZojPay0IqaQqDEL0IVa0KKUHpCnTQww3vn1_qszO7XLpvt1J9UUzYSA88LtyRg5yM90ZDMsYA-CxVFmBBQvBZA_19Re3mzdS01cIqMd_XseKIWNSsGXwoCgs0mo5yvN-yRANh_99R5mBtTh6xhxNM5B_G6e2zO6l7zO5_nQ7Cn7DrY6Ls3rbb1oeCLBFwSrHQpo4jCuWIlS93HMYwOmybwwZ5u0uXq9bziU51w8kPy4n_e3OBBgiROL9CPN36uOspcug99zhwv17NNzL5wEfLzztsIDcDjknxnWn9lP04-fz902kxZVcooq5FX5S20jGG2lZZOrA2Jymy0DqDSDFAFXTWKEiVtXLCZIi5RLRQ-5SUqJIr9TO216269IJxyBFRXKx8GUrsCcE4iFImWSmiXxML9m5e6eZqJNFo5MRNOoumIdE0k2gW7CPJ46YzcWAPFagZzaQZzb80Y8HezNJs8JuhgxDfpdV20xBdJVllgTN7Por55lHaUZ5FIV_-jym8Yg_otcbwl9dsr19v0wG7F3_355v1Ibsrfp1iWS_t4aC-fwD9OPZN
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Daratumumab-based+regimen+for+newly+diagnosed+multiple+myeloma+patients+with+paraskeletal+plasmacytomas%3A+a+retrospective+study+in+a+single+center&rft.jtitle=Hematology+%28Luxembourg%29&rft.au=Xu%2C+Shuiqing&rft.au=Chen%2C+Wenming&rft.au=Li%2C+Yanchen&rft.date=2024-12-01&rft.issn=1607-8454&rft.eissn=1607-8454&rft.volume=29&rft.issue=1&rft_id=info:doi/10.1080%2F16078454.2024.2431958&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_16078454_2024_2431958
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1607-8454&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1607-8454&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1607-8454&client=summon